The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Regulatory compliance
The TGA monitors and enforces regulatory compliance in relation to therapeutic goods. This supports consumer protection and a fair market for industry.
-
Further examples of counterfeit Ozempic-labelled products have been detected and stopped at the Australian border.
-
Takeda Pharmaceuticals Australia has issued a product alert for Vyvanse capsules due to minor packaging errors. The medication is safe to use as prescribed.
-
Magnum XXL capsules pose a serious risk to your health and should not be taken.
-
Summit Pharmacy Pty Ltd issued infringement notices for the alleged unlawful manufacturing of medicinal cannabis products
We have issued 4 infringement notices totalling $75,120 to Queensland based pharmacy Summit Pharmacy Pty Ltd, for the alleged unlawful manufacturing of medicinal cannabis products. -
Listed medicines requiring a warning statement
We will be initiating targeted compliance reviews of selected listed medicines that are required to display a warning statement -
Enforceable undertaking: Your Solution Compounding Pharmacy
We have accepted a court-enforceable undertaking from Your Solution Compounding Pharmacy Pty Ltd, regarding advertising of prescription-only compounded medicines for weight-loss.
-
Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
This plan outlines our compliance and education priorities for 2024-2025.
-
This fact sheet is for healthcare practitioners to help understand the rules surrounding importation of cosmetic injectables.